Non-invasive Rejuvenation of the Periorbital Area and Lower Eyelid

NCT ID: NCT07028203

Last Updated: 2025-06-19

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-05
• Study Completion Date: 2025-12-31

Brief Summary

The goal of this clinical trial is to determine the BTL-785-7-11 applicator effectiveness for an under-eye appearance improvement by evaluation of the periorbital area in healthy adult volunteers. The main question it aims to answer is:

Whether the BTL-785-7-11 applicator is able to improve the periorbital area post-treatment, as assessed by the analysis of 3D photographs.

Participants will complete four treatments and two follow-up visits.

Detailed Description

The study will evaluate the clinical efficacy and safety of the BTL-785 device with applicator BTL-785-7-11 for periorbital area rejuvenation.

The study has a prospective, multicenter, open-label, and one-arm design.

Subjects will be required to complete four (n=4) treatment visits and two (n=2) follow-up visits.

At the baseline visit, inclusion and exclusion criteria will be verified upon obtaining informed consent from the patient. Digital 2D and 3D photographs of the treatment area will be taken.

The treatment administration phase will consist of four (n=4) treatments, delivered 2 -14 days apart. The applicator will be placed outside the orbital rim, on the subject's inferior orbital portion of the orbicularis oculi muscles and lateral canthal edge-temporal area. Therapy time is set to 20 minutes. At the last therapy visit, the subject's digital 2D and 3D photographs of the treatment area will be collected. In addition, subjects will receive therapy comfort and subject satisfaction questionnaires to fill in.

During the 1-month and 3-month follow-up visits, the subjects will undergo 2D and 3D photographing of the treatment area, and the subject satisfaction questionnaires will be collected.

Safety measures will include documentation of adverse events (AE), which will be assessed after each procedure and at all follow-up visits.

Conditions

Periorbital Wrinkles; Periorbital Area; Under-eyes Dark Circles; Crows Feet

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment with BTL-785 with the applicator BTL-785-7-11

The treatment administration phase will consist of four treatment visits.

Group Type: EXPERIMENTAL

Treatment with BTL-785 with the applicator BTL-785-7-11

Intervention Type: DEVICE

The treatment administration phase will consist of four (n=4) treatments, delivered 2 -14 days apart. The applicator will be placed outside the orbital rim, on the subject's inferior orbital portion of the orbicularis oculi muscles and lateral canthal edge-temporal area. Therapy time is set to 20 minutes.

Interventions

Treatment with BTL-785 with the applicator BTL-785-7-11

The treatment administration phase will consist of four (n=4) treatments, delivered 2 -14 days apart. The applicator will be placed outside the orbital rim, on the subject's inferior orbital portion of the orbicularis oculi muscles and lateral canthal edge-temporal area. Therapy time is set to 20 minutes.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Healthy male or female subjects over 21 years of age seeking aesthetic improvement of the periorbital area
• Subjects should be able to understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form
• Presence of clearly visible aging signs in the periorbital area (e.g. under-eye bags, periorbital wrinkles) when the face is relaxed as deemed appropriate by the Investigator
• Subjects willing and able to abstain from partaking in any facial treatments other than the study procedure during study participation
• Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs of their face taken

Exclusion Criteria

• Lower eyelid malposition (ectropion, entropion, retraction)
• Blepharitis
• Prior lower eyelid fat removal, skin resection, eyelid surgery or orbital trauma in the past 6 months, prior dermatochalasis of lower eyelids surgical treatment in the past 6 months
• Filler injections in the treatment area and midface region within 3 months prior to the study participation
• Neuromodulator treatment in the periorbital area within 3 months prior to the study participation
• Tattoo(s) and/or permanent make-up in the intended treatment area
• Prior usage within 30 days before the screening or planned usage during the study of retinol, or any medication that can cause dermal hypersensitivity
• Bacterial or viral infection, acute inflammations
• Impaired immune system
• Isotretinoin in the past 12 months
• Skin-related autoimmune diseases
• Radiation therapy and chemotherapy
• Poor healing and unhealed wounds in the treatment area
• Metal implants near treatment area or neutral electrode
• Permanent implant near the area to be treated
• Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body
• Current condition or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles
• History of any type of malignant cancer
• Active collagen diseases
• Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)
• Pregnancy/nursing or IVF procedure
• History of bleeding coagulopathies, use of anticoagulants
• Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea
• Any surgical procedure in the treatment area within the last three months or before complete healing
• Poorly controlled endocrine disorders, such as diabetes
• Electroanalgesia without exact diagnosis of pain etiology
• Tuberculosis
• Hepatitis
• Febrile conditions
• Acute neuralgia and neuropathy
• Kidney or liver failure
• Sensitive disorders in the treatment area
• Varicose veins, pronounced edemas
• Skin dermabrasion, skin resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment
• Application in the area of chest, heart, carotid sinus, mouth (i.e. over the lips and in the near proximity) or over the eyes (i.e. over the eyeballs and eyelids)
• Serious psychopathological disorders (such as schizophrenia)
• Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy)
• Blood vessels and lymphatic vessels inflammation
• Scarring in the treatment area

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

BTL Industries Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Laser & Skin Surgery Medical Group, Inc.

Sacramento, California, United States

Art of Skin MD

Solana Beach, California, United States

Gentile Facial Plastic and Aesthetic Laser center

Youngstown, Ohio, United States

Countries

United States

Other Identifiers

BTL-785_CTUS1800

Identifier Type: -

Identifier Source: org_study_id